Oxford Biomedica completes acquisition of remaining stake in U.S. subsidiary

OXB has acquired the remaining 10% stake in its US subsidiary from Q32 Bio (QTTB), bringing its ownership, as planned, to 100%. As previously disclosed in the Company’s Preliminary Results on 9 April, OXB US exercised its call option on 1 March to acquire the final 10% interest in OXB US from Q32. The stake was originally held by Homology Medicines, which merged with Q32 in 2024. The transfer of Q32’s 10% holding to OXB US, means that OXB US is now wholly owned by OXB. OXB US was originally established in Bedford, MA, in 2022, as an AAV manufacturing and innovation business. The facility has since been fully integrated into OXB’s global network, successfully completing the tech transfer of its lentiviral platform to the site in 2024. Spanning 96,000 ft, the site offers lentiviral and AAV vector capabilities and has supported the onboarding of multiple new programmes in the US, as part of OXB’s global cell and gene therapy development and manufacturing network.